Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 7, 2008
JNCI Journal of the National Cancer Institute 2008 100(20):1417; doi:10.1093/jnci/djn391
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/20/1417-a    most recent
djn391v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

MEMO TO THE MEDIA

Older Renal Cancer Patients Appear to Benefit from Sorafenib Treatment

The first 10% of the full text of this article appears below.

Both older and younger patients with renal cancer derive similar benefit from sorafenib therapy and tolerate the drug equally well, according to a study published online October 7 in the Journal of the National Cancer Institute.

Although the risk of . . . [Full Text of this Article]

Contact:

Citation:


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
Tim Eisen, Stéphane Oudard, Cezary Szczylik, Gwenaelle Gravis, Hans Heinzer, Richard Middleton, Frank Cihon, Sibyl Anderson, Sonalee Shah, Ronald Bukowski, Bernard Escudier, and for the TARGET Study Group
J Natl Cancer Inst 2008 100: 1454-1463. [Abstract] [Full Text] [PDF]